Get ready for Tinted Finacea

A recently surfaced patent assigned to Intendis suggests that we might soon see a Tinted Finacea reach the market.

According to the patent application, a tinted formulation of Finacea had improved anti-inflammatory effects compared to regular Finacea – “Surprisingly, it was found that there was a further marked reduction in cytokine release in the cultures treated with azelaic acid and titanium dioxide-coated potassium aluminium silicate 3%”.

As a related note, we know from research from Dr. Gallo’s group that the active ingredient in Finacea, azelaic acid can decrease the expression of 2 substances thought to be important in rosacea – kallikrein 5 (KLK5) and cathelicidin.

Are You Excited?

I can’t say that the thought of a Tinted Finacea is terribly exciting. Personally I rely on a tinted sunscreen for coloring and would normally expect active topicals to just deliver their therapy and that is that. Also the amount of tint would need to exactly match the amount you need for coloring, whilst matching the optimal amount for the active ingredient too. Would a tint encourage you to apply too much or too little I wonder?

Given that the addition of particular pigments might increase the effectiveness of a particular treatment does make me reconsider my stance though.

Perhaps we might see a Tinted Metrogel one day too.

Would consider switching to Finacea if it was tinted ? Would it enhance your use of Finacea if it was providing you a tint?

Azelaic acid-comprising formulation with added pigment

The present patent application relates to an azelaic acid-comprising pharmaceutical composition, preferably an azelaic acid-comprising gel, with added pigment, which composition can be used, inter alia, for treating rosacea and acne, and also to a process for its preparation.

Agent: Intendis Gmbh – Berlin, DE

Filed: May 26, 2011

USPTO Applicaton #: #20120027862 – Class: 424490 (USPTO)

It is known that topical formulations comprising azelaic acid can be used for treating certain dermatological disorders, for example rosacea and acne.

These products can be present in various pharmaceutical forms, for example as cream, gel, lotion or foam. In some of the preparations of the prior art, use is also made of azelaic acid derivatives, for example dialkyl esters. In addition, some of the compositions also comprise other pharmaceutically active substances such as, for example, metronidazole (WO 2004/108143) or retinoids (WO 2007/082780).

However, it is most unclear whether there are any interactions between the therapy with azelaic acid-comprising formulations and these cosmetics. Dermatologists can not exclude that such cosmetics may have an unfavourable effect on the course of the therapy.

There is therefore a need to provide novel azelaic acid-comprising compositions which allow a therapy of rosacea and acne and at the same time solve the individual cosmetic problems, without having an unfavourable effect on the course of the therapy.

Accordingly, it is an object of the present invention to provide stable azelaic acid-comprising formulations, in particular with proven active compound concentrations, for example from 10 to 25% by weight of azelaic acid, in particular 15% by weight or else 20% by weight, of azelaic acid, for the therapy of rosacea and acne, and at the same time to solve the individual cosmetic problems without any unfavourable effect on the course of the therapy. In particular, relatively large amounts of pigment, which may affect stability, activity or else the compatibility of the overall formulation, should be avoided.

It has now been found that the addition of inorganic pigments to azelaic acid-comprising formulations resolves the problems described at the outset. Surprisingly, the combinations of azelaic acid and interference pigment showed improved antiinflammatory action compared to pure azelaic acid.

Furthermore, it has been found that stable pigment-comprising azelaic acid formulations can be prepared by a certain process. Here, the order of the process steps is important. In the process according to the invention, particular care has to be taken to avoid any rise in temperature during or after the addition.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.